abs3.txt	purpose		exposure	to	the	polyphenolic	plant	lignan	secoisolariciresinoldiglucoside	(sdg)	and	its	metabolite	enterolactone	(enl)	has	been	associated	withreduced	breast	cancer	progression		particularly	for	estrogen	receptor	alpha(erα)-negative	disease		and	decreased	preclinical	mammary	tumor	growth		however	while	preclinical	studies	have	established	that	sdg	and	enl	affect	measures	ofprogression	in	models	of	triple-negative	breast	cancer	(tnbc		a	subset	oferα-negative	disease)		the	molecular	mechanisms	underlying	these	effects	remainunclear	methods		c57bl/6	mice	were	fed	a	control	diet	(control		10%	kcal	from	fat)	orcontrol	diet	+	sdg	(sdg		100	mg/kg	diet)	for	8	weeks		then	orthotopicallyinjected	with	syngeneic	e0771	mammary	tumor	cells	(a	model	of	tnbc)		tumor	growthwas	monitored	for	3	weeks		the	role	of	reduced	nf-κb	signaling	in	sdg'santi-tumor	effects	was	explored	in	vitro	via	treatment	with	the	bioactive	sdgmetabolite	enl		in	addition	to	the	murine	e0771	cells		the	in	vitro	studiesutilized	mda-mb-231	and	mcf-7	cells		two	human	cell	lines	which	model	thetriple-negative	and	luminal	a	breast	cancer	subtypes		respectively	results		sdg	supplementation	in	the	mice	significantly	reduced	tumor	volume	andexpression	of	phospho-p65	and	nf-κb	target	genes	(p	<	0	05)		markers	ofmacrophage	infiltration	were	decreased	in	the	distal-to-tumor	mammary	fat	pad	ofmice	supplemented	with	sdg	relative	to	control	mice	(p	<	0	05)		in	vitro		enltreatment	inhibited	viability		survival		and	nf-κb	activity	and	target	geneexpression	in	e0771		mda-mb-231		and	mcf-7	cells	(p	<	0	05)		overexpression	ofrela	attenuated	enl's	inhibition	of	e0771	cell	viability	and	survival	conclusions		sdg	reduces	tumor	growth	in	the	e0771	model	of	tnbc		likely	via	amechanism	involving	inhibition	of	nf-κb	activity		sdg	could	serve	as	a	practicaland	effective	adjuvant	treatment	to	reduce	recurrence		but	greater	understandingof	its	effects	is	needed	to	inform	the	development	of	more	targetedrecommendations	for	its	use	
